Cue Biopharma (NASDAQ:), Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical firm creating a novel class of injectable biologics to selectively have interaction and modulate disease-specific T cells immediately inside the affected person’s physique, introduced at present that world-renowned immunologist and distinguished thought chief Dr. Rafi Ahmed, Ph.D., has joined its Scientific Advisory Board (SAB).

Dr. Ahmed’s analysis has considerably formed the scientific group’s present understanding of immunity within the context of viral infections and most cancers. His intensive work on defining T cell exhaustion together with detailing molecular underpinnings of T cell differentiation and effector responses have been seminal in establishing novel areas of analysis and therapeutic functions. His laboratory has pioneered extremely refined and modern mobile and molecular methods to review antigen-specific responses and immunological reminiscence in murine, primate, and human techniques.

“We’re most excited and honored to have Dr. Ahmed be part of our SAB,” stated Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma. “Rafi’s insights in defining the purposeful traits of potent T cell responses towards international threats, together with most cancers, are immediately pertinent to our IL-2-based CUE-100 sequence which selectively targets IL-2 to the tumor-specific T cells whereas avoiding broad activation of the immune system. The medical validation and tolerability of our strategy is exemplified by the maturing medical information noticed with our first medical candidate, CUE-101, in recurrent/metastatic head and neck squamous cell carcinoma, and within the potential of our second medical candidate, CUE-102, at the moment being evaluated in a Section 1 dose-escalation monotherapy trial, in a number of stable tumors. We look ahead to Rafi’s insights and contributions as we additional develop datasets that spotlight our differentiated and focused strategy to most cancers immunotherapy.”

Dr. Ahmed, added, “I’m delighted to be becoming a member of Cue Biopharma’s Scientific Advisory Board. The Immuno-STAT™ platform and biologics signify a differentiated strategy, demonstrating the flexibility to have interaction and activate disease-specific T cells inside the affected person’s physique with off-the-shelf molecules. As a brand new core member of the SAB, I look ahead to offering further translational immunology experience and accompany Cue Biopharma because it advances its medical applications. I’m excited with its potential to convey a lot wanted focused therapies to sufferers that may enhance medical efficiency and cut back life-threatening uncomfortable side effects.”

Dr. Ahmed is the Director of the Emory Vaccine Heart at Emory College. He’s additionally the co-leader of the Most cancers Immunology analysis program at Winship Most cancers Institute of Emory College and a Professor within the Division of Microbiology and Immunology on the Emory College Faculty of Medication. For his ground-breaking analysis contributions, Dr. Ahmed is an elected member of the Nationwide Academy of Science. He’s additionally acknowledged as a Georgia Analysis Alliance Eminent Scholar and a Fellow of the Academy of Immuno-Oncology.

About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical firm, is creating a novel class of injectable biologics to selectively have interaction and modulate disease-specific T cells immediately inside the affected person’s physique. The corporate’s proprietary platform, Immuno-STAT™ (Selective Focusing on and Alteration of T cells) and biologics are designed to harness the physique’s intrinsic immune system as T cell engagers with out the necessity for ex vivo manipulation or broad systemic modulation.

Headquartered in Boston, Massachusetts, we’re led by an skilled administration group and impartial Board of Administrators with deep experience in immunology and immuno-oncology in addition to the design and medical improvement of protein biologics.

For extra data please go to www.cuebiopharma.com and comply with us on Twitter at https://twitter.com/CueBiopharma.

Ahead-Wanting Statements
This press launch comprises forward-looking statements inside the that means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Alternate Act of 1934, as amended, which might be supposed to be lined by the secure harbor created by these sections. Such forward-looking statements embody, however aren’t restricted to, these concerning the corporate’s enterprise methods, plans and prospects. Ahead-looking statements, that are based mostly on sure assumptions and describe the corporate’s future plans, methods and expectations, can usually be recognized by means of forward-looking phrases corresponding to “consider,” “count on,” “might,” “will,” “ought to,” “would,” “might,” “search,” “intend,” “plan,” “aim,” “venture,” “estimate,” “anticipate,” “technique,” “future,” “possible” or different comparable phrases, though not all forward-looking statements comprise these figuring out phrases. All statements aside from statements of historic information included on this press launch concerning the corporate’s methods, prospects, monetary situation, operations, prices, plans and targets are forward-looking statements. Vital elements that might trigger the corporate’s precise outcomes and monetary situation to vary materially from these indicated within the forward-looking statements embody, amongst others, the corporate’s restricted working historical past, restricted money and a historical past of losses; the corporate’s capability to attain profitability; potential setbacks within the firm’s analysis and improvement efforts together with detrimental or inconclusive outcomes from its preclinical research, its capability to safe required U.S. Meals and Drug Administration (“FDA”) or different governmental approvals for its product candidates and the breadth of any accepted indication; hostile results brought on by public well being pandemics, together with COVID-19, together with doable results on the corporate’s trials; detrimental or inconclusive outcomes from the corporate’s medical trials or preclinical research or severe and sudden drug-related uncomfortable side effects or different questions of safety skilled by individuals in medical trials; delays and modifications in regulatory necessities, coverage and pointers together with potential delays in submitting required regulatory functions to the FDA; the corporate’s reliance on licensors, collaborators, contract analysis organizations, suppliers and different enterprise companions; the corporate’s capability to acquire satisfactory financing to fund its enterprise operations sooner or later; operations and medical the corporate’s capability to keep up and implement obligatory patent and different mental property safety; aggressive elements; basic financial and market circumstances and the opposite dangers and uncertainties described within the Threat Elements and in Administration’s Dialogue and Evaluation of Monetary Situation and Outcomes of Operations sections of the corporate’s most lately filed Annual Report on Kind 10-Okay and any subsequently filed Quarterly Report(s) on Kind 10-Q. Any forward-looking assertion made by the corporate on this press launch is predicated solely on data at the moment accessible to the corporate and speaks solely as of the date on which it’s made. The corporate undertakes no obligation to publicly replace any forward-looking assertion, whether or not written or oral, that could be made infrequently, whether or not on account of new data, future developments or in any other case.

Investor Contact
Marie Campinell
Senior Director, Company Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com

Media Contact
Maya Romanchuk
LifeSci Communications
mromanchuk@lifescicomms.com